Navidea Biopharmaceuticals, Inc.
NAVB
$0.0001
$0.000.00%
| 09/30/2023 | 06/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.49% | 14.47% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.21% | 0.24% | |||
| Operating Income | 12.21% | -0.24% | |||
| Income Before Tax | -61.88% | 5.63% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -61.88% | 5.63% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -137.39% | 508.58% | |||
| EBIT | 12.21% | -0.24% | |||
| EBITDA | 12.34% | -0.26% | |||
| EPS Basic | -118.81% | 367.04% | |||
| Normalized Basic EPS | 60.45% | -25.53% | |||
| EPS Diluted | -118.81% | 367.04% | |||
| Normalized Diluted EPS | 60.45% | -25.53% | |||
| Average Basic Shares Outstanding | 105.97% | 47.74% | |||
| Average Diluted Shares Outstanding | 105.97% | 47.74% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
